MANAGEMENT OF HELLP SYNDROME BEFORE DELIVERY: A COMPREHENSIVE SYSTEMATIC REVIEW
DOI:
https://doi.org/10.61841/5rsvc467Keywords:
HELLP syndrome, prenatal, treatmentAbstract
Background: HELLP syndrome, a rare and serious complication during pregnancy, poses significant risks to both mother and fetus. Early management of HELLP syndrome before delivery may improve the outcomes for patients. This study aims to systematically review literatures on HELLP syndrome management before delivery in the last 10 years.
Methods: This systematic review complied with the PRISMA 2020 standards and focused on full-text English literature published between 2014 and 2024. Articles such as editorials and review papers from the same journal, as well as submissions lacking a DOI, were excluded from consideration. Literature was sourced from online platforms like PubMed and SagePub.
Result: We found 1629 articles on PubMed and 560 articles on SagePub. Restricting our search to the past decade (20142024), PubMed presented 507 articles, whereas SagePub presented 288 articles. From these, we selected 5 papers meeting our criteria, with 3 from PubMed and 2 from SagePub.
Conclusion: The main treatment approach for HELLP syndrome involves stabilizing the mother and ensuring timely delivery. Various strategies, including the use of corticosteroids and glucocorticoids, have been explored to reduce the associated morbidity and mortality.
References
Adorno M, Maher-Griffiths C, Grush Abadie HR. HELLP Syndrome. Crit Care Nurs Clin North Am. 2022 Sep;34(3):277–88.
Khalid F, Mahendraker N, Tonismae T. HELLP Syndrome. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 [cited 2024 Feb 20]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK560615/
Wallace K, Harris S, Addison A, Bean C. HELLP Syndrome: Pathophysiology and Current Therapies. Curr Pharm Biotechnol. 2018;19(10):816–26.
Cadoret F, Guerby P, Cavaignac-Vitalis M, Vayssiere C, Parant O, Vidal F. Expectant management in HELLP syndrome: predictive factors of disease evolution. J Matern Fetal Neonatal Med. 2021 Dec;34(24):4029–34.
Kang S, Zhou L, Wang X, Li Y, Wang Y. Effectiveness of high-dose glucocorticoids on hemolysis, elevating liver enzymes, and reducing platelets syndrome. J Int Med Res [Internet]. 2019 Feb 1 [cited 2024 Feb 20];47(2):738–47. Available from: https://doi.org/10.1177/0300060518809783
Cui C, Ma S, Qiao R. Prenatal Plasma Fibrinogen Level Predicts Postpartum Hemorrhage of Patients With HELLP Syndrome. Clin Appl Thromb Hemost [Internet]. 2020 Jan 1 [cited 2024 Feb 20];26:1076029619894057. Available from: https://doi.org/10.1177/1076029619894057
Poimenidi E, Metodiev Y, Archer NN, Jackson R, Bangash MN, Howells PA. Haemolysis, elevated liver enzymes and low platelets: Diagnosis and management in critical care. Journal of the Intensive Care Society [Internet]. 2022 Aug 1 [cited 2024 Feb 21];23(3):372–8. Available from: https://doi.org/10.1177/17511437211025410
Sun WJ, Hu J, Zhang Q, Shan JM. Administration of corticosteroid therapy for HELLP syndrome in pregnant women: evidences from seven randomized controlled trials. Hypertens Pregnancy. 2023 Dec;42(1):2276726.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Licensing
Ninety Nine Publication publishes articles under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This licensing allows for any use of the work, provided the original author(s) and source are credited, thereby facilitating the free exchange and use of research for the advancement of knowledge.
Detailed Licensing Terms
Attribution (BY): Users must give appropriate credit, provide a link to the license, and indicate if changes were made. Users may do so in any reasonable manner, but not in any way that suggests the licensor endorses them or their use.
No Additional Restrictions: Users may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
